请使用支持JavaScript的浏览器! --R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug
banner
当前位置: 首页 > 产品中心 > > R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug

R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug

  • 产品编号: AF2249-100 ug
  • 美  元  价: $359.00
  • 会  员  价: 待定
  • 品       牌: R&D Systems
  • 产       地: 美国
  • 公       司:
  • 产品分类: ref="." class="index">首页 > R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug
  • 公司分类:
:100 ug
R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug
  • R&D Systems/Human NKp44/NCR2 Antibody/AF2249/100 ug
商品介绍
  • Species Reactivity
    Human
  • Specificity
    Detects human NKp44/NCR2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human (rh) NKp30, rhNKp46, and rhNKp80 is observed.
  • Source
    Polyclonal Goat IgG
  • Purification
    Antigen Affinity-purified
  • Immunogen
    Mouse myeloma cell line NS0-derived recombinant human NKp44/NCR2
    Gln22-Pro190, predicted
    Accession # O95944
  • Formulation
    Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
  • Endotoxin Level
    <1.5 eu="" per="" 1="" μg="" of="" the="" antibody="" by="" the="" lal="">
  • Label
    Unconjugated
  • Western Blot
    0.1 µg/mL
    Recombinant Human NKp44/NCR2 Fc Chimera (Catalog # 2249-NK)
  • AgoNIST Activity
    0.2-0.6 µg/mL
    See below
  • Reconstitution
    Reconstitute at 0.2 mg/mL in sterile PBS.
  • Shipping
    The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
  • StABIlity & Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    • 12 months from date of receipt, -20 to -70 °C as supplied.
    • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
    • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
  • References:
    1. Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
    2. Cantoni, C. et al. (1999) J. Exp. Med. 189:787.
    3. Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
    4. Vitale, M. et al. (1998) J. Exp. Med. 187:2065.
    5. Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
    6. Pende, D. et al. (1999) J. Exp. Med. 190:1505.
    7. Arnon, T. et al. (2001) Eur. J. Immunol. 31:2680.
  • Long Name:
    NK Cell Activating Receptor
  • Entrez Gene IDs:
    9436 (Human)
  • Alternate Names:
    CD336 antigen; CD336; LY95; LY95lymphocyte antigen 95 homolog (activating NK-receptor; NK-p44); lymphocyte antigen 95 (activating NK-receptor; NK-p44); Lymphocyte antigen 95 homolog; natural cytotoxicity triggering receptor 2; Natural killer cell p44-related protein; NCR2; NK cell activating receptor (NKp44); NK cell-activating receptor; NKp44; NK-p44dJ149M18.1

    Background:

    NKp44, along with NKp30 and NKp46, constitute a group of receptors termed "Natural Cytotoxicity Receptors" (NCR) (1). These receptors are expressed almost exclusively by NK cells and play a major role in triggering NK-mediated killing of most tumor cell lines. No rodent ortholog to NKp44 has been identified. Human NKp44, also known as NCR2, is a 44 kDa type I transmembrane glycoprotein that is characterized by the presence of one extracellular V-like immunoglobulin domain (2). It is synthesized as a 276 amino acid (aa) precursor that contains a 21 aa signal sequence, a 171 aa extracellular region, a 21 aa transmembrane segment and a 63 aa cytoplasmic tail. Alternate splicing in both the cytoplasmic tail and extracellular region generates multiple isoforms of unknown significance. The Ig-like region is unaffected. A physical association with the ITAM-bearing accessory protein, DAP12, occurs via a charged residue in the NKp44 transmembrane domain. Ligation of NKp44 with a specific antibody results in phosphorylation of DAP12 (3) and activation of target cell lysis in a redirected killing assay (4). NKp44 is absent from resting NK cells but is up‑regulated upon activation with IL-2. Activation-induced expression occurs in the CD56dim CD16+ NK subset that accounts for more than 85% of NK cells found in peripheral blood and spleen, as well as the CD56bright CD16- NK subset that constitutes the majority of NK cells in lymph node and tonsil (5). Studies with neutralizing antibodies reveal that NKp44 is partially responsIBLe for triggering lytic activity against several tumor cell types (2, 6). Blocking any of the individual NCRs results in partial inhibition of tumor cell lysis, but nearly complete inhibition of lysis is observed if all three receptors are blocked simultaneously (6). NKp44 has also been implicated in recognition of virus-infected cells through its capacity to bind to viral hemagglutinins (7).

    品牌介绍

          R&D Systems位于美国的明尼苏达州,一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年,公司推出第一个产品--富血小板血浆质控品;1981年,公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中,R&D Systems仍持续开发各种血控品产品。

      1985年,作为公司推出的第一个科研试剂产品,也是全球第一家将该产品进行商业化生产的产品,R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子,TGF-beta1蛋白在多种细胞中进行表达,并作为胞外信号分子参与免疫功能,细胞增殖和细胞分化等生物学过程。该产品推出后,公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

      天然蛋白类产品的成功推广,加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部(现Biotechnology事业部)。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较,DNA重组技术生产的蛋白产品其成本更低,产量更高,完全摆脱原料的限制。1989年,Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体,并于1990年开发了第一个ELISA试剂盒。

      2014年2月10日,R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。

     

    自营商城图标
    厂家直采
    全球直采模式 正品优价
    正品保障图标
    正品保障
    厂家直发 有线跟踪
    解放采购图标
    正规清关
    CIF100%正规报关,提供发票
    及时交付图标
    及时交付
    限时必达 不达必赔
    在线客服
    客服电话

    4000-520-616

    微信交流